文章：

半乳糖凝集素-9 mRNA表达在慢性淋巴细胞白血病中的预后潜力评估

Prognostic Potential of Galectin-9 mRNA Expression in Chronic Lymphocytic Leukemia

原文发布日期：11 November 2023

DOI: 10.3390/cancers15225370

类型: Article

开放获取: 是

英文摘要：

Galectin-9 (Gal-9), very poorly characterized in chronic lymphocytic leukemia (CLL), was chosen in our study to examine its potential role as a CLL biomarker. The relation of Gal-9 expression in malignant B-cells and other routinely measured CLL markers, as well as its clinical relevance are poorly understood. Gal-9 mRNA expression was quantified with RT-qPCR in purified CD19+ B-cells of 100 CLL patients and analyzed in the context of existing clinical data. Our results revealed the upregulation of Gal-9 mRNA in CLL cells. High Gal-9 mRNA expression was closely associated with unfavorable prognostic markers. In addition, Gal-9 expression in leukemic cells was significantly elevated in CLL patients who did not respond to the first-line therapy compared to those who did respond. This suggests its potential predictive value. Importantly, Gal-9 was an independent predictor for the time to treatment parameters. Thus, we can suggest an adverse role of Gal-9 expression in CLL. Interestingly, it is possible that Gal-9 expression is induced in B-cells by EBV infection, so we determined the patients’ EBV status. Our suggestion is that EBV coinfection could worsen prognosis in CLL, partly due to Gal-9 expression upregulation caused by EBV.

摘要翻译： 

半乳糖凝集素-9（Gal-9）在慢性淋巴细胞白血病（CLL）中的特征尚不明确，本研究选择该分子以探讨其作为CLL生物标志物的潜在价值。目前对恶性B细胞中Gal-9表达与常规CLL标志物的关联及其临床意义认知有限。本研究通过RT-qPCR技术对100例CLL患者纯化的CD19+ B细胞进行Gal-9 mRNA定量检测，并结合临床数据进行分析。结果显示CLL细胞中Gal-9 mRNA表达显著上调，其高表达与不良预后标志物密切相关。值得注意的是，相较于治疗应答者，一线治疗无应答患者的白血病细胞中Gal-9表达水平显著升高，提示其潜在的预测价值。更重要的是，Gal-9可作为治疗时间参数的独立预测因子，这表明Gal-9表达在CLL进展中可能发挥负面作用。有趣的是，EBV感染可能诱导B细胞表达Gal-9，因此我们检测了患者的EBV感染状态。我们认为EBV共感染可能通过上调Gal-9表达而加剧CLL预后不良，这为理解CLL进展机制提供了新视角。

原文链接：

Prognostic Potential of Galectin-9 mRNA Expression in Chronic Lymphocytic Leukemia